Moderate To Severe Ulcerative Colitis
The primary objective of this study is to evaluate the long-term safety and tolerability of an investigational medication in participants with moderate to severe ulcerative colitis (UC).
To qualify, you must:
- Be 18-80 years old
- Diagnosis of UC established at least 3 months prior to enrollment by clinical and endoscopic evidence
Contribute to the advancement of medical knowledge and treatments, while receiving expert medical care under close supervision.
The M3 Wake Research Network has powered innovation with over 9,100 Successful Clinical Trials in patients from 6 months to 85 years.
Patient safety is paramount with strict protocols and ethical guidelines, minimizing risks and ensuring thorough monitoring throughout the trial.